Tarceva is an important drug with good--maybe great--revenue prospects. But since FDA approval of the drug, earlier this month, OSI Pharmaceuticals’ stock price has declined. What will the drug’s revenues be? Why have analysts lowered their expectations for the drug from blockbuster status? We separate fact and fiction.
